Filter Results
:
(1,010)
Show Results For
-
All HBS Web
(1,010)
- People (4)
- News (251)
- Research (595)
- Events (7)
- Multimedia (25)
- Faculty Publications (385)
Show Results For
-
All HBS Web
(1,010)
- People (4)
- News (251)
- Research (595)
- Events (7)
- Multimedia (25)
- Faculty Publications (385)
- April 1999 (Revised May 2000)
- Case
Pilgrim Drug Company
David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of an earlier case.
View Details
Burton, M. Diane, and Jeffrey L. Bradach. "Pilgrim Drug Company." Harvard Business School Case 499-062, April 1999. (Revised May 2000.)
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly...
View Details
Keywords:
Health;
Economics;
Government and Politics;
Innovation and Invention;
Research;
Science;
Biotechnology Industry;
Health Industry;
Pharmaceutical Industry
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
- October 1997 (Revised September 2003)
- Case
Eli Lilly and Company: Drug Development Strategy (A)
By: Stefan H. Thomke, Ashok Nimgade and Paul Pospisil
Describes how Eli Lilly and Co. tries to accelerate its new drug development process with the aid of "combinatorial chemistry"--a rapidly emerging and revolutionary approach to preclinical drug discovery. The product manager of a potential blockbuster migraine drug...
View Details
Keywords:
Chemicals;
Finance;
Innovation and Invention;
Time Management;
Markets;
Product Development;
Organizations;
Business Processes;
Problems and Challenges;
Business and Stakeholder Relations;
Competition;
Pharmaceutical Industry
Thomke, Stefan H., Ashok Nimgade, and Paul Pospisil. "Eli Lilly and Company: Drug Development Strategy (A)." Harvard Business School Case 698-010, October 1997. (Revised September 2003.)
- June 2020
- Article
Evaluation of Prescription Drug Monitoring Program Integration with Hospital Electronic Health Records by US County-Level Opioid Prescribing Rates
By: A Jay Holmgren and Nate Apathy
Prescription drug monitoring programs (PDMPs) have become a widely embraced policy solution to the opioid epidemic in the US. PDMPs offer prescribers a comprehensive view of patients’ controlled substance prescription history and can be used to monitor and reduce...
View Details
Keywords:
Prescription Drug Monitoring Programs;
PDMPs;
Electronic Health Records;
Hospitals;
Health Care and Treatment;
Information Technology;
Integration;
Performance Evaluation
Holmgren, A Jay, and Nate Apathy. "Evaluation of Prescription Drug Monitoring Program Integration with Hospital Electronic Health Records by US County-Level Opioid Prescribing Rates." JAMA Network Open 3, no. 6 (June 2020).
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures.
View Details
Keywords:
Business Model;
Information Technology;
Market Entry and Exit;
Biotechnology Industry;
Pharmaceutical Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- December 1976 (Revised September 1980)
- Case
Drug Fair, Inc. (A)
By: John P. Kotter and Leonard A. Schlesinger
Kotter, John P., and Leonard A. Schlesinger. "Drug Fair, Inc. (A)." Harvard Business School Case 477-063, December 1976. (Revised September 1980.)
- 02 Mar 2016
- News
Drug ad backlash doesn’t deter Cambridge biotech
- Fast Answer
Pharmaceuticals: drug retail prices
Where can I find drug prices? You may begin with: Cortellis - Drug price data. Access is available to HBS AND HU students, staff and faculty onsite at Baker Library (users must be logged in by Baker...
View Details
- March 2015
- Teaching Note
CVS Health: Promoting Drug Adherence
Email mking@hbs.edu for a courtesy copy.
This Teaching Note explains the theory of the case and teaching plan for the case: CVS Health: Promoting Drug Adherence (515010). The case finds Helena Foulkes, Executive... View Details
This Teaching Note explains the theory of the case and teaching plan for the case: CVS Health: Promoting Drug Adherence (515010). The case finds Helena Foulkes, Executive... View Details
Keywords:
Medication Adherence;
Affordable Care Act (ACA);
Marketing Strategy;
Communication Strategy;
Customer Value and Value Chain;
Decisions;
Health Care and Treatment;
Goals and Objectives;
Resource Allocation;
Marketing Communications;
Consumer Behavior;
Measurement and Metrics;
Service Delivery;
Behavior;
Motivation and Incentives;
Social Issues;
Information Technology;
Value Creation;
Health Industry;
Pharmaceutical Industry;
Insurance Industry;
Public Relations Industry;
Retail Industry;
United States
John, Leslie, John Quelch, and Robert Huckman. "CVS Health: Promoting Drug Adherence." Harvard Business School Teaching Note 515-086, March 2015. (Email mking@hbs.edu for a courtesy copy.)
- October 1987 (Revised November 1994)
- Case
Boston Fights Drugs (A): Designing Communications Research
Describes in detail the research mounted by five individuals with a $20,000 budget to combat drug abuse among Boston's school-going population. Using the focus group methodology they discover that most of the current anti-drug advertising is useless. They create their...
View Details
Keywords:
Budgets and Budgeting;
Misleading and Fraudulent Advertising;
Communication Intention and Meaning;
Brands and Branding;
Performance Evaluation;
Research and Development;
Segmentation;
Pharmaceutical Industry;
Boston
Rangan, V. Kasturi. "Boston Fights Drugs (A): Designing Communications Research." Harvard Business School Case 588-031, October 1987. (Revised November 1994.)
- August 2008 (Revised May 2009)
- Background Note
Note on Generic Drugs in the European Union
By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S.
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Government Legislation;
Health Care and Treatment;
Trademarks;
Brands and Branding;
Pharmaceutical Industry;
European Union;
United States
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
Vogel, Matthew, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, and Benjamin N. Rome. "Cost of Exempting Sole Orphan Drugs from Medicare Negotiation." JAMA Internal Medicine 184, no. 1 (January 2024): 63–69.
- 15 Jun 2021
- News
Podcast: How Biosimilars Are Affecting the Drug Markets
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India.
View Details
Keywords:
Price;
Health Care and Treatment;
Marketing Strategy;
Product Launch;
Planning;
Biotechnology Industry;
Pharmaceutical Industry;
India
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
- 1999
- Chapter
The Economics of Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "The Economics of Drug Discovery." Chap. 5 in Pharmaceutical Innovation, edited by Ralph Landau, Basil Achilladelis, and Alexander Scriabine, 308–331. Philadelphia: Chemical Heritage Press, 1999.
- 11 Jun 2010
- News
Drug companies pool Alzheimer's information
- February 2005 (Revised April 2006)
- Case
Rx Depot: Importing Drugs from Canada
By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot...
View Details
Keywords:
Courts and Trials;
Entrepreneurship;
Intellectual Property;
Laws and Statutes;
Pharmaceutical Industry;
Canada;
United States
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
- January 2007 (Revised January 2007)
- Background Note
Note on the U.S. Food and Drug Administration
By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller
Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.
View Details
Keywords:
Health;
Governance Compliance;
Policy;
Product Development;
Government and Politics;
Pharmaceutical Industry;
Medical Devices and Supplies Industry;
Biotechnology Industry;
Public Administration Industry;
United States
Higgins, Robert F., Richard G. Hamermesh, and Virginia Fuller. "Note on the U.S. Food and Drug Administration." Harvard Business School Background Note 807-050, January 2007. (Revised January 2007.)
- 27 Sep 2015
- News